Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sight Sciences, Inc.SGHT · Entity 5537 | Director · Chief Technology Officer | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sight Sciences, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,975,075 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 7,797 · Balance 1,975,075 F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.87 to $9.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (i) 1,823,160 shares of Common Stock, and (ii) 151,915 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs").
F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.87 to $9.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes (i) 1,823,160 shares of Common Stock, and (ii) 151,915 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:40 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 7,797 | $9.05 | $70,555.05 |
DisclosureSEC source: 0001193125-26-414275 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,975,075 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.87 to $9.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 1,823,160 shares of Common Stock, and (ii) 151,915 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| July 06, 2026 Filed Jul 6, 2026 23:34 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 7,418 | $5.51 | $40,858.34 |
DisclosureSEC source: 0001193125-26-296594 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,982,872 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $5.37 to $5.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 1,813,950 shares of Common Stock, and (ii) 168,922 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 20:28 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 8,168 | $3.48 | $28,424.64 |
DisclosureSEC source: 0001193125-26-142233 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,990,290 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $3.43 to $3.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 1,804,359 shares of common stock, and (ii) 185,931 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units that have not yet vested. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:28 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,270 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001193125-26-064098 · ownership.xml · derivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,270 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of stock options ("Options") awarded to the Reporting Person under the Issuer's equity incentive plan. F3 · derivative.exercise_date: The grant of Options made to the Reporting Person vested and became exercisable as to 25% of the underlying shares on January 1, 2017, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options became fully vested and exercisable on January 1, 2020. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:28 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionCommon Stock | 21,270 | $0.23 | $4,892.10 |
DisclosureSEC source: 0001193125-26-064098 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,998,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of stock options ("Options") awarded to the Reporting Person under the Issuer's equity incentive plan. F2 · balance_after: Includes (i) 1,795,520 shares of common stock, and (ii) 202,938 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units that have not yet vested. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:49 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 64,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039562 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,977,188 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2026 and continuing through December 31, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $420,000 divided by the closing price of the Common Stock on the grant date, which was February 3, 2026. F2 · balance_after: Includes (i) 1,774,250 shares of Common Stock, and (ii) 202,938 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:56 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 4,836 | $6.62 | $32,014.32 |
DisclosureSEC source: 0001193125-26-018131 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,912,273 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 1,774,250 shares of common stock, and (ii) 138,023 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 00:08 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 3,695 | $7.48 | $27,638.60 |
DisclosureSEC source: 0001193125-26-004994 · ownership.xml · nonDerivative · entry 3 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,917,109 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F4 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:08 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 3,051 | $7.82 | $23,858.82 |
DisclosureSEC source: 0001193125-26-004994 · ownership.xml · nonDerivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,920,804 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F3 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.71 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:08 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 2,914 | $7.43 | $21,651.02 |
DisclosureSEC source: 0001193125-26-004994 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,923,855 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.29 to $8.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 26, 2025 Filed Dec 30, 2025 21:11 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,270 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001193125-25-337102 · ownership.xml · derivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,270 Underlying: Common Stock · 21,270 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan. F4 · derivative.exercise_date: The grant of stock options ("Options") made to the Reporting Person vested and became exercisable as to 25% of the underlying shares on January 1, 2017, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on January 1, 2020. Read SEC document |
| December 26, 2025 Filed Dec 30, 2025 21:11 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionCommon Stock | 21,270 | $0.23 | $4,892.10 |
DisclosureSEC source: 0001193125-25-337102 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,926,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan. F2 · balance_after: Includes (i) 1,758,996 shares of common stock, and (ii) 167,773 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested. F3 · balance_after: The Reporting Person previously reported a grant of 28,100 RSUs on a Form 4 filed on February 11, 2022 (which was subsequently included under Table 1 on a Form 4 filed on January 5, 2023) and a grant of 39,100 RSUs on a Form 4 filed on March 21, 2023, which were awarded on February 9, 2022 and March 16, 2023, respectively. Of these RSU grants, 43,375 shares were inadvertently excluded from the Reporting Person's beneficially owned shares. The reported balance includes these previously excluded shares. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:53 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 6,033 | $3.27 | $19,727.91 |
DisclosureSEC source: 0001193125-25-230557 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,864,992 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 22:36 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0000950170-25-097015 · ownership.xml · derivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan. F2 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 22:36 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionCommon Stock | 40,000 | $0.12 | $4,800.00 |
DisclosureSEC source: 0000950170-25-097015 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,871,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 01:25 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 5,679 | $4.17 | $23,704.15 |
DisclosureSEC source: 0000950170-25-094422 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,831,025 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 01:55 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 5,980 | $2.30 | $13,771.94 |
DisclosureSEC source: 0000950170-25-050863 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,836,704 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| March 11, 2025 Filed Mar 14, 2025 01:53 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 98,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039077 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,842,684 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2025 and continuing through December 31, 2028, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $275,000 divided by the closing price of the Common Stock on the grant date, which was March 11, 2025. The RSUs have no expiration date. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 02:58 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 5,423 | $2.78 | $15,081.36 |
DisclosureSEC source: 0000950170-25-007515 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,744,118 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $2.68 to $2.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 11:09 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 3,829 | $3.26 | $12,478.71 |
DisclosureSEC source: 0000950170-25-003722 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,749,541 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 02:48 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 3,111 | $3.52 | $10,956.94 |
DisclosureSEC source: 0000950170-25-002533 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,753,370 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $3.465 to $3.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 01:53 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 3,167 | $5.99 | $18,957.66 |
DisclosureSEC source: 0000950170-24-112705 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,756,481 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 23:54 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 3,128 | $6.42 | $20,072.38 |
DisclosureSEC source: 0000950170-24-081730 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,759,648 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| April 03, 2024 Filed Apr 4, 2024 23:24 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 3,128 | $5.08 | $15,887.11 |
DisclosureSEC source: 0000950170-24-041985 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,762,776 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:40 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 108,645 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016709 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,765,904 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2024 and continuing through December 31, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $465,000 divided by the closing price of the Common Stock on the grant date, which was February 14, 2024. The RSUs have no expiration date. F2 · balance_after: Includes 15,102 shares of Common Stock issuable upon the Reporting Person's exercise of options that shall vest within 60 days of the date hereof subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 21:43 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 3,414 | $5.16 | $17,629.90 |
DisclosureSEC source: 0000950170-24-005833 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,642,157 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:43 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Tax withholdingCommon Stock | 2,425 | $5.17 | $12,542.10 |
DisclosureSEC source: 0000950170-24-002611 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,645,571 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes (i) 7,025 shares of Common Stock issued in connection with the vesting of RSUs on January 1, 2024, and (ii) 9,775 shares of Common Stock that will be issued in connection with the vesting of RSUs on January 15, 2024, subject to the Reporting Person's continued service through such date. Read SEC document |
| November 24, 2023 Filed Nov 29, 2023 01:16 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionStock Option (Right to Buy) · Derivative | 150,000 | $0.11 Strike: $0.11 | $16,500.00 |
DisclosureSEC source: 0000950170-23-066529 · ownership.xml · derivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2024-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan. F1 · derivative.underlying_shares: Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan. Read SEC document |
| November 24, 2023 Filed Nov 29, 2023 01:16 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionCommon Stock | 150,000 | $0.11 | $16,500.00 |
DisclosureSEC source: 0000950170-23-066529 · ownership.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,631,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of stock options awarded to the Reporting Person under the Issuer's equity incentive plan. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 10:15 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0000899243-23-009242 · doc4.xml · derivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-16 F3 · shares: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable in 48 equal monthly installments with the first installment vesting commencing on January 1, 2023 through January 1, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. F3 · derivative.exercise_date: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable in 48 equal monthly installments with the first installment vesting commencing on January 1, 2023 through January 1, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 10:15 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 39,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009242 · doc4.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,485,790 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments from January 15, 2024 through January 15, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). F2 · balance_after: Reflects shares of Common Stock beneficially owned by the Reporting Person as of the date hereof, excluding RSUs that do not vest within 60 days of this filing pursuant to Rule 13d-3(d)(1)(i). Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 11:30 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Tax withholdingCommon Stock | 2,431 | $12.21 | $29,682.51 |
DisclosureSEC source: 0000899243-23-000828 · doc4.xml · nonDerivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,485,790 F3 · shares: Reflects shares of Common Stock withheld by the Issuer to cover the Reporting Person's tax liability in connection with the vesting of RSUs. F4 · price: Reflects the closing sale price of the Issuer's Common Stock as reported on The Nasdaq Global Select Market on December 30, 2022. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 11:30 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 28,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000828 · doc4.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,488,221 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person on February 9, 2022 under the Issuer's 2021 Incentive Award Plan (such grant, the "RSU Grant"), as reported in Table II on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on February 11, 2022. Of the RSUs awarded to the Reporting Person under the 2022 RSU Grant, 25% vested on January 1, 2023, and an additional 25% vest on each of January 1, 2024, 2025, and 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The RSUs have no expiration date. F2 · balance_after: Includes 7,025 shares of Common Stock issued in connection with the January 1, 2023 vesting of the 2022 RSU Grant. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 20:05 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0000899243-22-031869 · doc4.xml · derivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2027-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 20:05 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionCommon Stock | 40,000 | $0.23 | $9,200.00 |
DisclosureSEC source: 0000899243-22-031869 · doc4.xml · nonDerivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,481,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2022 Filed Dec 30, 2025 21:11 UTC Amendment | Sight Sciences, Inc. SGHT · Entity 5537 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001193125-25-337097 · ownership.xml · derivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,540 Underlying: Common Stock · 40,000 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The grant of stock options ("Options") made to the Reporting Person vested and became exercisable as to 25% of the underlying shares on January 1, 2017, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on January 1, 2020. F3 · derivative.expiration_date: The original Form 4 filing identified the expiration date of the relevant Options as 01/08/2027. This amendment corrects the expiration date of the relevant Options to February 28, 2026. F1 · balance_after: Includes 1,441,196 shares that were previously reported as beneficially owned on the Reporting Person's Form 3 filed on July 14, 2021, as well as 7,460 shares that were acquired by the Reporting Person upon exercise of options prior to the Issuer's completion of the Initial Public Offering in July 2021 that should have been included under Column 2 of Table I of the Form 3 but were inadvertently included as shares underlying options with an exercise price of $0.23 that expire on February 28, 2026 under Column 3 of Table II of the Form 3. F4 · balance_after: Excludes the 7,460 shares that were previously inadvertently included as described in footnote (1) to this Form 4. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:05 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantStock Option (Right to Buy) · Derivative | 112,400 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0000899243-22-005825 · doc4.xml · derivative · entry 2 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,400 Underlying: Common Stock · 112,400 shares Expires 2032-02-09 F3 · derivative.exercise_date: The options vest and become exercisable in 48 substantially equal monthly installments with the first installment vesting on February 1, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:05 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantRestricted Stock Units · Derivative | 28,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-005825 · doc4.xml · derivative · entry 1 Badawi David · CIK 0001870825 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,100 Underlying: Common Stock · 28,100 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The Restricted Stock Units vest as to 25% on each of January 1, 2023; January 1, 2024; January 1, 2025 and January 1, 2026. The Restricted Stock Units have no expiration date. F2 · derivative.expiration_date: The Restricted Stock Units vest as to 25% on each of January 1, 2023; January 1, 2024; January 1, 2025 and January 1, 2026. The Restricted Stock Units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.